We’ll send you latest news updates through the day. The new plant will support “our objective to expand our …, Abu Dhabi – Mubasher: The ordinary general meeting (OGM) of Gulf Pharmaceutical Industries (Julphar) has approved a proposal to distribute cash dividends of 16 fils per share (16% of the capital) for fiscal year 2016. Net profits reached AED 44.1 million ($12.01 million) in Q1-17, …, Abu Dhabi – Mubasher: Julphar’s chief financial officer Jerome Carle on Wednesday announced that his company will open its manufacturing plant in Saudi Arabia on Thursday, 20 April. By raising AED 500 million, the company will finance its turnaround plan and put …, Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) incurred AED 62.5 million in net losses attributable to shareholders during the first quarter of 2020, down from AED 89.1 million in the year-ago period. We continue to roll-out our cost-saving programmes, which will position our business well to maximise cash flow generation.”. The deal involves local distribution and marketing with Zulekha, which specialises in …, Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) is planning to establish its first factory for cancer drugs in Abu Dhabi, Al Ittihad newspaper reported, citing Julphar’s chairman Faisal bin Saqr Al Qasimi. All data are 15 minutes late during market session, Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) posted AED 83.2 million accumulated losses as of the end of the second quarter (Q2) of 2020, representing 12.7% of the capital. “We will stay focused on the transformational goals laid out in our strategic plan and follow through with our new product launches and portfolio optimisation. “Anything that will boost the local pharmaceutical industry and offer customers more choice is a move in the right direction,” the CEO said. This website intends to use cookies to improve the site and your experience. “The temporary ban on the export of our products applies only to Saudi Arabia and Bahrain. The largest generic pharmaceutical manufacturer in the MENA region reported AED 1.45 billion in sales for 2016, it …, Data is delayed 15 minutes during market session, This website is licensed by Saudi Arabia's Ministry of Culture and Information, All Rights Reserved - Mubasher Info © 2005 - 2020, Julphar's rights issue oversubscribed 2.3 times, Julphar launches AED 500m rights issue to improve capital profile, Julphar’s loss down 30% in Q1-20; accumulated losses at AED 566m, Julphar to resume exports to Saudi Arabia after two-year suspension, Julphar to extinguish accumulated losses via capital cut, Julphar’s loss surges 163.5% YoY in Q3-19, Julphar to offset AED 561.7m accumulated losses, Julphar’s CEO resigns; last working day in 2M, Julphar posts Q1 interim consolidated financial results, Julphar names new chairman, vice chairman, UAE’s Julphar, Russian Biocad ink tumor treatment deal, Julphar, BD ink deal to provide disposable insulin pens in UAE, UAE’s Julphar to build AED 250m pharma plant in Egypt, Julphar unit inks deal with Zulekha Group, UAE’s Julphar to build plants in Abu Dhabi, Kuwait, UAE’s Julphar to open Saudi plant Thursday, Julphar posts AED 1.45bn sales in 2016, finalises KSA plant, {{'components.pagination.ng.next' | translate}}. These cookies are used to improve your experience and provide more personalized service to you. Going operational with the plant will be a major boost for the company in what is one of the largest health care markets in the region. Furthermore, the OGM agreed …, Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) on Sunday announced its financial results for the full year 2016. Net sales fell to AED 114.6 …, Abu Dhabi – Mubasher: The Saudi Food and Drug Authority (SFDA) has lifted the temporary suspension on the exports of Gulf Pharmaceutical Industries (Julphar) to Saudi Arabia. Julphar is still negotiating with Saudi authorities to get the ban lifted. - The company will offer 500 million new shares with a nominal value of AED 1. Terms of Use UAE pharma giant to launch production at new plant even though an export ban still stands. Register to read and get full access to gulfnews.com, By clicking below to sign up, you're agreeing to our If you require further information and/or do not wish to have cookies placed when using the site, refer to our, Gulf Pharmaceutical Industries (Julphar) Reports Financial Results for Q2 2020, Gulf Pharmaceutical Industries (Julphar) rights issue oversubscribed by 2.3 times, Julphar resumes sales of products in Bahrain and Kuwait, Gulf Pharmaceutical Industries (Julphar) launches AED 500 million rights issue. - Julphar announces 90% increase in sales in comparison to Q2 2019 - Strong result improvement with 6% EBITDA margin in Q2 2020, - Julphar launched AED 500 million rights issue at an offer price of AED 1 per share on 29th June 2020 - Total bids received from existing rightsholders stood at AED 1.14 billion on application which closed on 12th July 2020, After an inspection of Julphar facilities, the Gulf Health Council and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait has lifted the temporary suspension on the export of Julphar products to Bahrain and Kuwait. With UAE and Gulf health authorities keeping a close watch on the mounting cost of health care and of drug prices, entities such as Julphar through local/regional production capacities ensure drug prices remain in check.